<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="147841">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01714687</url>
  </required_header>
  <id_info>
    <org_study_id>CPR005030</org_study_id>
    <nct_id>NCT01714687</nct_id>
  </id_info>
  <brief_title>Comparison of Balloon Sinuplasty In-Office Versus Medical Management for Recurrent Acute Sinusitis Patients (CABERNET)</brief_title>
  <acronym>CABERNET</acronym>
  <official_title>Comparison of Balloon Sinuplasty In-Office Versus Medical Management for Recurrent Acute Sinusitis Patients: A Randomized Controlled Study (CABERNET)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acclarent</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acclarent</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This post-market study aims to compare health outcomes for Recurrent Acute Rhinosinusitis
      (RARS) patients treated with balloon sinus dilation (BSD) versus medical management alone.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in disease-specific patient-reported quality of life (QOL)</measure>
    <time_frame>24 weeks post treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in disease-specific patient-reported quality of life</measure>
    <time_frame>24 and 48 weeks post treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in disease-specific and general health-related quality of life</measure>
    <time_frame>8, 24 and 48 weeks post treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in disease-specific medication usage</measure>
    <time_frame>24 and 48 weeks post treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Missed days work/school and medical care visits due to sinusitis</measure>
    <time_frame>24 and 48 weeks post treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of sinus infections</measure>
    <time_frame>48 weeks post treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects electing procedure (cross-over)</measure>
    <time_frame>48 weeks post treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-procedure return to normal activity (RTNA)</measure>
    <time_frame>2 weeks post treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Recurrent Acute Rhinosinusitis</condition>
  <arm_group>
    <arm_group_label>balloon sinus dilation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Balloon sinus dilation will be conducted in-office under local anesthesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>medical therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Medical therapy as needed per subject's specific disease and as determined by the investigators' clinical judgment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>balloon sinus dilation</intervention_name>
    <arm_group_label>balloon sinus dilation</arm_group_label>
    <other_name>balloon sinuplasty</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>medical therapy</intervention_name>
    <arm_group_label>balloon sinus dilation</arm_group_label>
    <arm_group_label>medical therapy</arm_group_label>
    <other_name>medical management</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  19 years of age or greater

          -  diagnosis of recurrent acute rhinosinusitis

          -  suitable candidate for office-based procedure

          -  willing and able to read and sign informed consent and remain compliant with protocol
             and study procedures

          -  able to read and understand English

        Exclusion Criteria:

          -  diagnosis of chronic rhinosinusitis

          -  prior sinus surgery

          -  physician determined need for ancillary procedures

          -  known immune deficiency, ciliary dysfunction and/or autoimmune disease

          -  clinically significant illness that may interfere with evaluation of the study

          -  participation in clinical studies 6 months prior to study participation

          -  pregnant or lactating females
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashley Sikand, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ear Nose and Throat Consultants of Nevada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Sillers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alabama Nasal and Sinus Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>England</last_name>
    <email>lenglan1@its.jnj.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Alabama Nasal and Sinus Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ENT of Georgia</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ear Nose and Throat Consultants of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ENT Associates of Texas</name>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <zip>75070</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 12, 2014</lastchanged_date>
  <firstreceived_date>October 24, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sinusitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
